Tandem糖尿病，DexCom在ADA会议后看到了弱点

2024-06-25 00:06

As the American Diabetes Association's 84th Scientific Sessions wraps up Monday, two key players in the diabetes treatment space are trading down.
In early afternoon trading, Tandem Diabetes Care (NASDAQ:TNDM) is down ~6%, while DexCom (NASDAQ:DXCM) is off ~4%.
Both companies made presentations at the conference. Tandem released results from a quality of life survey from users of its Tandem Mobi insulin pump. Meanwhile, DexCom released additional data on the benefits of its continuous glucose monitors.
In addition, Insulet (PODD) released positive results from the pivotal SECURE-T2D trial on the Omnipod 5 insulin delivery system. Shares are trading flat.
In a note, Oppenheimer noted that the planned August launch of DexCom's over-the-counter CGM, Stelo, should be a driver for the company.
The Tandem and DexCom declines could be a reaction to positive phase 2 data released this morning on Altimmune's (ALT) weight loss candidate, pemvidutide.

More on DexCom, Tandem Diabetes